Last reviewed · How we verify
TDF treatment
TDF treatment, developed by New Discovery LLC, is an antiviral medication primarily used for the treatment of HIV and chronic hepatitis B. Despite its efficacy, it does not have an FDA label, which may limit its market potential. The drug works by inhibiting viral DNA synthesis, but concerns over renal and bone toxicity have been noted. TDF is currently in the pipeline for additional indications, and the company is exploring its use in combination therapies. Safety profiles and commercial prospects will be crucial for its future success.
At a glance
| Generic name | TDF treatment |
|---|---|
| Also known as | Viread, Tenofovir, TDF, Hepatitis B-IgG, Hepatitis B vaccine |
| Sponsor | New Discovery LLC |
| Drug class | Nucleotide reverse transcriptase inhibitor (NtRTI) |
| Target | Viral reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
Pipeline indications
Common side effects
Key clinical trials
- Spotting Syphilis: A Dual Point-of-Care Syphilis Screening Initiative in a Low-Resource Healthcare Setting (NA)
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) (PHASE2, PHASE3)
- Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018) (PHASE3)
- ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention (NA)
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure on TLD in Sub-Saharan Africa (NA)
- The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients (NA)
- REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE: A Multi-Center, Single-Arm, Open-Label, Phase 4 Study Assessing the Safety and Efficacy of B/F/TAF in HIV-Positive Adults Returning to Care After Experiencing a Treatment Interruption of ≥12 Weeks (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TDF treatment CI brief — competitive landscape report
- TDF treatment updates RSS · CI watch RSS
- New Discovery LLC portfolio CI